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Aims Fractalkine (CX3CL1) is a membrane-bound chemokine that signals through the G protein-coupled receptor
CX3CR1 that is implicated in the development of atherosclerosis. We have previously reported that CX3CR1 is
expressed by primary human coronary artery smooth muscle cells (CASMC), where it mediates chemotaxis
towards CX3CL1. We sought to determine the effect of CX3CL1 on CASMC survival and proliferation and elucidate
the signalling mechanisms involved.
Methods
and results
CX3CL1 signiﬁcantly reduces staurosporine-induced apoptosis of CASMC, as quantiﬁed by caspase 3 immunostaining
and Annexin-V ﬂow cytometry. Furthermore, CX3CL1 is a potent mitogen for primary CASMC and induces phos-
phorylation of extracellular signal-regulated kinase (ERK) and Akt, measured by western blotting. Inhibition of either
ERK or phosphoinositide 3-kinase (PI3K) signalling abrogates proliferation, while only PI3K signalling is involved in the
anti-apoptotic effects of CX3CL1. We describe a novel and speciﬁc small molecule antagonist of CX3CR1
(AZ12201182) which abrogates the mitogenic and anti-apoptotic effects of CX3CL1 on CASMC. Pharmacological
inhibition of the epidermal growth factor receptor (EGFR) blocks CASMC survival and DNA synthesis, indicating
a previously undocumented role for EGFR signalling in response to CX3CL1 involving release of a soluble EGFR
ligand. Speciﬁcally, CX3CL1 induces shedding of epiregulin and increases epiregulin mRNA expression 20-fold
within 2 h. Finally, antibody neutralization of epiregulin abrogates the mitogenic effect of CX3CL1.
Conclusion We have demonstrated two novel and important functions of CX3CL1 on primary human SMCs: anti-apoptosis and
proliferation, both mediated via epiregulin-induced EGFR signalling. Our data have important implications in vascular
pathologies including atherosclerosis, restenosis, and transplant accelerated arteriosclerosis, where the balance of
SMC proliferation and apoptosis critically determines both plaque stability and vessel stenosis.
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Chemokines (chemoattractant cytokines) are low molecular weight
proteins responsible for coordinating cell trafﬁcking in both
homeostatic and inﬂammatory contexts.
1 Around 50 chemokines
have been cloned to date, and they are divided into four families
(C, CC, CXC and CX3C) based on the location of key structural
cysteine residues. Fractalkine or CX3CL1 is the only member of
the CX3C chemokine family and displays an unusual membrane-
bound structure with the chemokine domain attached to the mem-
brane via a mucin-like stalk where it is capable of mediating
adhesion of cells expressing the G protein-coupled receptor
CX3CR1.
2 CX3CL1 expression has been detected on activated
endothelial cells,
3 smooth muscle cells (SMCs),
4 and macrophages
5
and its expression is enhanced by inﬂammatory stimuli, including
TNFa, IFNg, and LPS.
4 CX3CL1 can be cleaved from the cell
surface in response to inﬂammatory stimuli by TNFa-converting
enzyme (TACE/ADAM17).
6 Soluble CX3CL1 is then able to act
as a classical chemoattractant for leukocytes
7 and also SMCs
expressing CX3CR1.
8
CX3CL1 is involved in the development of numerous inﬂamma-
tory pathologies including rheumatoid arthritis
9 and graft rejec-
tion.
10 Several lines of evidence implicate CX3CL1 in the
pathogenesis of atherosclerosis. First, two non-synonymous single-
nucleotide polymorphisms in CX3CR1 (V249I and T280M) have
been associated with an altered risk of coronary artery disease
and stroke in large population-based studies.
11,12 Secondly,
cx3cr1
2/2 apoe
2/2 animals show smaller atherosclerotic lesions
containing fewer macrophages at numerous anatomical sites,
13
while cx3cl1
2/2 or
þ/2 apoe
2/2 animals show smaller lesions at
the brachiocephalic artery.
14 Finally, CX3CL1 and CX3CR1
expression can be detected in human atherosclerotic plaques,
while expression in normal areas of vessel is low.
8 Work from
our laboratory demonstrated the expression of CX3CL1 in mono-
nuclear cell inﬁltrates of coronary artery plaques, while CX3CR1
was found localized to SMCs, particularly those in close contact
with CX3CL1-positive macrophages.
8
Knockout studies have demonstrated a clear role for CX3CL1 in
leukocyte migration into nascent atherosclerotic plaques.
However, functional roles for CX3CR1 expression on human
SMCs remain relatively unexplored. We sought to investigate
whether CX3CL1 is a survival factor and mitogen for human cor-
onary artery SMCs (CASMC) in vitro, and elucidate the signalling
pathways required for these activities.
2. Methods
2.1 Materials
All reagents for cell culture were obtained from Invitrogen unless
otherwise stated. All other reagents were purchased from Sigma
Aldrich unless otherwise speciﬁed. Recombinant human CX3CL1 che-
mokine domain was purchased from R&D systems, and CXCL8 and
PDGF-BB were from Peprotech. EGF and bFGF were from Promocell.
AG1478 and staurosporine were from Calbiochem, and GM6001 from
Biomol. Anti-pERK-1/2, anti-pAkt, anti-cleaved caspase 3, and total Akt
antibodies were from Cell Signalling Technology. ERK2 antibody was
from Santa Cruz. Annexin-V FITC was from Becton Dickinson. ECL
Supersignal reagents and the BCA protein assay kit were from
Perbio. Fluorescently conjugated secondary antibodies were from
Jackson ImmunoResearch.
2.2 Cell culture
Primary human CASMC obtained from normal regions of vessel from
ﬁve independent donors were obtained from Lonza and cultured
according to manufacturer’s instructions using SmGM-2 media. The
HCM-601EB medial SMC line was grown in DMEM supplemented
with 10% FCS and 750 mg/mL G418 and has been described
previously.
15 All experiments were performed following 48 h serum-
starvation in serum-free media (SFM, DMEM/0.1% BSA) unless
otherwise stated.
2.3 Measurement of apoptosis
Apoptosis was quantiﬁed by immunostaining of cleaved caspase 3,
detection of caspase 3/7 activity using the Caspase-Glo assay
(Promega) and by annexin V/propidium iodide staining and ﬂow cyto-
metry according to manufacturer’s protocols. Further details and
representative FACS plots are provided in Supplementary material
online.
2.4 [
3H]-thymidine incorporation
as a measure of cellular proliferation
Detailed experimental information can be found in Supplementary
material online. Brieﬂy, cells were grown in 96-well plates until 80%
conﬂuent, serum-starved for 48 h, then agonist stimulated for 24 h
prior to the addition of 0.1 mCi/well methyl-[
3H]-thymidine (speciﬁc
activity 1 mCi/mL, GE Healthcare) for 4 h and scintillation counting.
2.5 Ki67 staining as a measure of cell
proliferation
Cells were grown in 4-well chamber slides and treated exactly as for
the tritiated thymidine incorporation assay. Cells were ﬁxed for
20 min in 4% paraformaldehyde, permeabilized in 0.2% Triton
X-100/PBS for 5 min, and blocked with 3% BSA/0.1% Triton X-100/
PBS for 15 min. Cells were stained with mouse anti-human Ki67
antibody (Dako) for 1 h followed by goat anti-mouse FITC for
30 min. Nuclei were counterstained with DAPI and cells examined
by ﬂuorescence microscopy.
2.6 Signalling assays
Serum-starved cells grown in 6-well plates were pre-treated with or
without antagonist for the indicated times before agonist addition
and lysate preparation. Further details can be found in Supplementary
material online.
2.7 Western blotting
Protein lysates (20 mg) were resolved on a 10% SDS–PAGE gel, and
transferred to Hybond-C nitrocellulose membrane (GE Healthcare).
Blots were blocked with 10% w/v non-fat-dried milk/Tris buffered
saline/0.05% Tween-20 (TBS-T) for 90 min. Blots were incubated
with primary antibody overnight at 48C, then incubated for 90 min
with appropriate secondary antibodies which were detected using
the Supersignal chemiluminescence kit and autoradiography.
Western blots were stripped for 30 min at 508C in stripping buffer
(67 mmol/L Tris–HCl, 2% SDS, 100 mmol/L 2-Mercaptoethanol).
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RT–PCR
RNA was isolated using the RNeasy RNA isolation kit (Qiagen)
according to manufacturer’s instructions, reverse transcribed and
PCR reactions carried out using Quantitect SYBR green mastermix
(Qiagen) according to manufacturer’s instructions. Further details
can be found in Supplementary material online.
2.9 Epiregulin detection by ﬂow cytometry
CASMC were grown in T25 ﬂasks, serum-starved as above, and
treated for the indicated times with PMA (phorbol-12-
myristate-13-acetate) or CX3CL1 and stained with anti-epiregulin anti-
body (clone 183 629, R&D systems) according to the manufacturer’s
protocol. See the Supplementary material online for more details.
2.10 Data analysis
All data were analysed using GraphPad Prism software (version 4.03).
Statistical signiﬁcance was assessed by one-way ANOVA and Bonferro-
ni’s, Tukey’s, or Dunnett’s post-test for comparisons between three or
more groups.
3. Results
3.1 CX3CL1 has anti-apoptotic effects
on primary human SMCs via CX3CR1
WeﬁrstsoughttoestablishwhetherCX3CL1couldblockapoptosis
of primary human CASMC induced by staurosporine. Treatment
with staurosporine (0.5 mmol/L) for 6 h induced a signiﬁcant
increase in the number of cells staining positively for cleaved
caspase 3: around 35% of cells in the population were cleaved
caspase 3
þ (P , 0.001, Figure 1A and D). Cells stained with isotype
control antibody showed no detectable staining (data not shown).
In addition, cells treated with staurosporine showed the hallmarks
of apoptosis, including nuclear condensation and fragmentation
(Figure 1C and D). Pre-treatment with CX3CL1 (30 nmol/L) for
30 min prior to the addition of staurosporine signiﬁcantly blocked
caspase 3 cleavage by around 50% (P , 0.01, Figure 1A).
To conﬁrm these ﬁndings, the activity of caspases 3 and 7 was
quantiﬁed using the Caspase-Glo 3/7 assay (Promega), which
measures cleavage of a luminescent caspase substrate. Treatment
with staurosporine induced caspase 3/7 activation (P , 0.001)
which was signiﬁcantly blocked by pre-treatment with 30 nmol/L
CX3CL1 (P , 0.001, Figure 1B).
Using a third assay to measure apoptosis induction, we quanti-
ﬁed annexin-V staining by ﬂow cytometry. Treatment with stauros-
porine (0.5 mmol/L) for 6 h induced a signiﬁcant increase in the
number of cells binding annexin-V FITC: around 50% of the cells
in the population (P , 0.001, Figure 1E). This was signiﬁcantly
reduced by pre-treatment with CX3CL1 (30 nmol/L) for 30 min
prior to staurosporine treatment (P , 0.05, Figure 1E).T o
conﬁrm that the effects of CX3CL1 were mediated via the
CX3CR1 receptor, we utilized a speciﬁc small-molecule antagonist
of the receptor AZ12201182 (see Supplementary material online,
Tables S2 and S3 for information on potency and speciﬁcity). Cyto-
toxicity assays conﬁrmed that the drug showed no detectable tox-
icity and did not have any pro-apoptotic effect in annexin-V binding
assays at the dose used (Figure 1F and data not shown). Pre-
treatment of the cells for 1 h with 500 nmol/L AZ12201182
prior to the addition of CX3CL1 abrogated the pro-survival
effect (P , 0.01, Figure 1F), indicating that the anti-apoptotic
effects of CX3CL1 on primary human CASMC are mediated via
CX3CR1.
3.2 CX3CL1 is a mitogen for primary
human SMCs and the SMC line
HCM-601EB
Since CX3CL1 has pro-survival effects on SMCs, we next sought to
determine whether CX3CL1 could induce human SMC prolifer-
ation in vitro. Using primary CASMC in a tritiated thymidine incor-
poration assay to measure de novo DNA synthesis, CX3CL1
induced a dose-dependent increase in DNA synthesis with an
average proliferation index in ﬁve donors of 8.8+1.42 in response
to 30 nmol/L CX3CL1 (P , 0.01, Figure 2A). The proliferation
index varied between donors, ranging from 2.5- to 17-fold in
response to 30 nmol/L CX3CL1. Using a previously described
CASMC line: HCM-601EB
15 in the same assay, CX3CL1 induced
a dose-dependent increase in DNA synthesis with an average pro-
liferation index of 23.1+1.22 for a dose of 30 nmol/L CX3CL1
(P , 0.01, Figure 2B).
These data were validated with a single dose of CX3CL1 and a
positive control (PDGF-BB) using two alternative methods of
measuring proliferation: Ki67 staining and total cell counting.
CX3CL1 (30 nmol/L) was found to signiﬁcantly increase both the
total cell number and the number of Ki67
þ cells (i.e. those in inter-
phase) to a similar extent as 1 nmol/L PDGF-BB in CASMC (P ,
0.05, Figure 2C; P , 0.001, Figure 2D).
To assess whether the mitogenic effects of CX3CL1 are
mediated via CX3CR1, we used the small molecule antagonist
AZ12201182 at a range of doses in a tritiated thymidine incorpor-
ation assay. Pre-treatment of cells with 10–500 nmol/L
AZ12201182 for 1 h prior to the addition of CX3CL1 signiﬁcantly
blocked DNA synthesis, with complete blockade of the CX3CL1
response at 500 nmol/L (P , 0.001, Figure 2E). AZ12201182 had
no effect on the DNA synthesis in response to CXCL8
(30 nmol/L) or 1% FCS, indicating a speciﬁc blockade of prolifer-
ation in response to CX3CL1 (Figure 2F).
3.3 CX3CL1 induces ERK and Akt
phosphorylation in human CASMC
We next investigated the signalling pathways involved in CX3-
CL1-mediated proliferation, initially focusing on extracellular
signal-regulated kinase (ERK): a serine/threonine kinase known to
be a key regulator in proliferation, survival, and differentiation.
CX3CL1 stimulated ERK 1/2 phosphorylation within 10 min
(Figure 3A). CX3CL1-induced ERK phosphorylation was completely
abolished following treatment with pertussis toxin (PTX) or a
MAPK/ERK kinase (MEK) inhibitor U0126 (Figure 3A). We then
assessed whether CX3CL1 treatment induced phosphorylation
of Akt: a key regulator in cell survival. CX3CL1 stimulated Akt
phosphorylation within 5 min and this was also completely
blocked by PTX and a phosphoinositide 3-kinase (PI3K) inhibitor
LY294,002 (Figure 3B). MTS assays demonstrated that neither
PTX, LY294,002 nor U0126 had any detectable cytotoxicity at
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dependent pathway, and the involvement of both ERK and PI3K in
CX3CL1 signalling in SMCs.
3.4 The mitogenic and anti-apoptotic
effects of CX3CL1 require Gai, ERK,
and PI3K signalling
To conﬁrm whether anti-apoptosis and/or proliferation were
dependent on ERK or PI3K signalling, we investigated the effect of
U0126 and LY294,002 on caspase 3 cleavage and tritiated thymidine
incorporation. CX3CL1-induced anti-apoptosis was blocked by the
PI3K inhibitor (P , 0.05), but not the MEK inhibitor (Figure 3C). In
contrast, the mitogenic effect of CX3CL1 on DNA synthesis was
completely blocked by both the MEK inhibitor and the PI3K inhibi-
tor (P , 0.001, Figure 3D). Both DNA synthesis (P , 0.001,
Figure 3E) and anti-apoptosis (P , 0.01, Figure 3C)w e r ea b r o g a t e d
by pre-treatment with PTX, indicating both are mediated via a Gai-
dependent pathway. In contrast, PTX had no effect on DNA syn-
thesis induced by PDGF-BB, indicating that the effects of PTX are
speciﬁc (Figure 3F). Taken together, these experiments show that
ERK and PI3K activity downstream of Gai are necessary to drive
Figure 1 CX3CL1 has anti-apoptotic effects on primary human CASMC that are blocked by the CX3CR1 inhibitor AZ12201182. (A) CASMC
were pre-treated +30 nmol/L CX3CL1 for 30 min prior to the addition of 0.5 mmol/L staurosporine or vehicle (DMSO) for 6 h. Cells were
stained with anti-cleaved caspase 3 antibody and nuclei stained with DAPI. Data expressed as percent cleaved caspase 3
þ cells, 750–1300 cells
counted per treatment. (B) Cells were treated as in (A) and after staurosporine treatment were incubated with Caspase-Glo 3/7 reagent to
quantify caspase activity. (C and D) Representative images ( 1000 magniﬁcation) showing vehicle treated (C) and staurosporine treated (D)
cells stained with anti-cleaved caspase 3 antibody and DAPI. (E) Cells were treated as in (A) and after staurosporine treatment were
stained with annexin-V FITC and propidium iodide and analysed by ﬂow cytometry to calculate the number of apoptotic cells (annexin-V
þ,
propidium iodide
2). (F) CASMC were pre-treated with 500 nmol/L AZ12201182 (AZ1220) then treated +CX3CL1 followed by staurosporine
treatment as in (E). All data shown as mean+SEM. Data analysed with one-way ANOVA and Tukey’s post hoc test. ***P , 0.001 relative to
untreated, þP , 0.05, þþP , 0.01, þþþP , 0.001 relative to staurosporine treated. ##P , 0.01 relative to CX3CL1 treated. (A) Data from
two donors, four independent experiments. (B) Data from three donors, four independent experiments. (E) Data from three independent
experiments, three ﬂasks per treatment in each experiment. (F) Data from two independent experiments, three ﬂasks per treatment in
each experiment.
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activity is required for the anti-apoptotic effects of CX3CL1.
3.5 CX3CL1-induced DNA synthesis and
anti-apoptosis requires epidermal growth
factor receptor activity
A number of mitogens acting via GPCRs are known to transduce
signals via transactivation of tyrosine kinase receptors such as
the epidermal growth factor receptor (EGFR). This can involve
intracellular transactivation of the EGFR by an activated GPCR
or can be mediated via metalloprotease-dependent cleavage of a
membrane bound EGFR ligand which is then able to activate
nearby EGFRs.
16 Phenylephrine, for example, binds to the
a1-adrenoreceptor and induces release of heparin-binding
EGF-like growth factor (HB-EGF) and transactivation of the
EGFR, leading to SMC proliferation.
17 Two chemokines
(CXCL12 and CCL11) have recently been shown to regulate the
expression of matrix metalloproteases in SMCs via a mechanism
involving EGFR activation.
18
Figure 2 CX3CL1 is a mitogen for primary human CASMC and this effect is blocked by the CX3CR1 inhibitor AZ12201182. (A) CASMC were
serum-starved for48 h to induce quiescence prior tostimulation with CX3CL1 for 24 h. A 4 h tritiatedthymidine pulsewasappliedand incorpor-
ation measured by scintillation counting. Data expressed as proliferation index: fold change over untreated. (B) The SMC line HCM-601EB was
treated with CX3CL1 as in (A). (C) Cells were grown in chamber slides and treated as for part (A) with PDGF-BB (1 nmol/L) or CX3CL1
(30 nmol/L). Cells were stained with anti-Ki67 antibody and DAPI, data are expressed as% Ki67
þ cells in the population. (D) Cells were treated
as in (C) and the number of cells per high power ﬁeld quantiﬁed. (E) Cells were pre-treated for 1 h with the indicated dose of AZ12201182
(AZ1220) or vehicle, prior to treatment with CX3CL1 as in part (A). (F) Cells were pre-treated for 1 h with 500 nmol/L AZ12201182 prior to
treatmentwith30 nmol/LCXCL8or1%v/vFCSandmeasurementofDNAsynthesisasinpart (A).Alldatashownasmean+SEM.Dataanalysed
withone-wayANOVAandDunnett’sposthoctest.*P , 0.05,**P , 0.01,***P , 0.001relativetountreated. þþP , 0.01, þþþP , 0.001rela-
tivetoCX3CL1treated.(A)Datafromﬁvedonors,greaterthanﬁveindependentexperiments.(B)Datafromgreaterthanﬁveindependentexper-
iments. (C and D) Data from three independent experiments. (E and F) Data from three independent experiments.
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anti-apoptotic and mitogenic effects of CX3CL1 using pharmaco-
logical inhibitors. We used the EGFR kinase inhibitor AG1478 to
block both the intracellular and extracellular pathways of EGFR
activation and the broad-spectrum metalloprotease inhibitor
GM6001 to block the extracellular EGFR activation pathway. To
ensure the inhibitors were speciﬁc for the EGFR, CASMC were
treated with the ligands EGF, bFGF, and PDGF-BB. AG1478 com-
pletely blocked DNA synthesis in response to EGF (P , 0.001),
but had no effect on the response to PDGF-BB or bFGF, indicating
a speciﬁc blockade of the EGFR alone (Figure 4A). MTS assays
demonstrated that neither AG1478 nor GM6001 showed any
detectable cytotoxicity at the doses used (data not shown).
Using cleaved caspase 3 staining, cells were pre-treated with
either AG1478 or GM6001 for 30 min, then CX3CL1 (30 nmol/L)
was added for 30 min before the addition of staurosporine for
6 h. Both drugs blocked the pro-survival effect of CX3CL1 (P ,
0.05, Figure 4B), indicating the involvement of the EGFR and the
extracellular activation pathway. In a tritiated thymidine incorpor-
ation assay, both AG1478 and GM6001 again completely
Figure 3 The mitogenic and anti-apoptotic effects of CX3CL1 require Gai, ERK, and PI3K signalling. (A) CASMC were serum-starved for 48 h,
then pre-treated +200 ng/mL pertussis toxin (PTX) for 2 h or U0126 (10 mmol/L) for 1 h, prior to the addition of 30 nmol/L CX3CL1 for the
indicated times. Cell lysates were prepared, and western blotted for pERK before stripping and re-probing with total ERK antibody. (B)C A S M C
were treated as in (A), and pre-treated with PTX or LY294,002 (10 mmol/L) for 1 h before CX3CL1 stimulation and western blotting for pAkt and
total Akt. (C) CASMC were pre-treated for 2 h with PTX or for 1 h with U0126/LY294,002 prior to the addition of 30 nmol/L CX3CL1 followed
by staurosporine treatment for 6 h and staining as in Figure 1A.( D) A tritiated thymidine incorporation assay was carried out as in Figure 1 following
1 h pre-treatment with U0126, LY294,002, or vehicle (DMSO). (E and F) CASMC were pre-treated with PTX for 2 h prior to the addition of
CX3CL1 or PDGF-BB, before tritiated thymidine incorporation was measured as described in Figure 2. Data shown as mean+SEM. Data analysed
with one-way ANOVA and Bonferroni’s multiple comparison post hoc test. *P , 0.05, **P , 0.01, ***P , 0.001 relative to CX3CL1 treated.
þþP , 0.01 relative to staurosporine treated. (A and B) Data are representative of three independent experiments from three donors. (C)
Data from two donors, three independent experiments. (D–F) Data from three donors, three independent experiments.
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Figure 4C and D, respectively) showing a requirement for EGFR
activation in proliferation.
We then sought to establish the time-course of EGFR
involvement in CX3CL1 signalling. Primary CASMC were
treated with AG1478 or GM6001 either 30 min prior to, or
0–8 h after the addition of CX3CL1 and DNA synthesis
measured. It was found that the addition of AG1478 could be
delayed until 6 h after agonist addition and still have an inhibitory
effect on DNA synthesis, whereas after 8 h this effect was lost
(Figure 4E). Similarly, GM6001 still inhibited DNA synthesis
when added 4 h after CX3CL1 treatment (Figure 4F). This
implies that EGFR signalling occurs during the ﬁrst 4–6 h of
CX3CL1 addition.
To conﬁrm whether EGFR signalling was required to induce ERK
and Akt activation, we used the EGFR inhibitor AG1478 and the
metalloprotease inhibitor GM6001 in signalling assays. CX3CL1
stimulated ERK phosphorylation within 10 min and this was unaf-
fected by pre-treatment with either inhibitor (Figure 4G), indicating
that ERK signalling occurs directly via CX3CR1. In contrast, Akt
Figure 4 The mitogenic and anti-apoptotic effects of CX3CL1 are mediated via EGFR activation. (A) CASMC were serum-starved for 48 h,
then pre-treated for 30 min with AG1478 (1 mmol/L) prior to the addition of EGF (100 pmol/L), FGF (100 pmol/L), or PDGF-BB (1 nmol/L)
and DNA synthesis quantiﬁed. (B) CASMC were pre-treated for 30 min with AG1478, GM6001 (10 mmol/L), or vehicle (DMSO), then treated
for 30 min +30 nmol/L CX3CL1 before the addition of 0.5 mmol/L staurosporine for 6 h. Cleaved caspase 3 staining was performed as in
Figure 1A.( C and D) CASMC were treated with AG1478, GM6001, or DMSO as in (B) prior to the addition of CX3CL1 for 24 h and quanti-
ﬁcation of DNA synthesis. (E and F) CASMC were treated with AG1478 for the indicated times either prior to or following CX3CL1 addition.
Data shown as percent of 3 nmol/L CX3CL1 response. (G) Serum-starved CASMC were pre-treated with or without vehicle (V, DMSO),
AG1478 (AG; 1 mmol/L), or GM6001 (GM; 10 mmol/L) for 1 h, prior to the addition of 30 nmol/L CX3CL1 for the indicated times. Cell
lysates were prepared and western blotted for pERK and total ERK2 expression. (H) Cells were treated as in (G) and western blotted for
pAkt and total Akt. All data shown as mean+SEM. Data analysed with one-way ANOVA and Dunnett’s or Bonferroni’s multiple comparison
post hoc test. *P , 0.05, **P , 0.01, ***P , 0.001 relative to CX3CL1 treated. þþP , 0.01 relative to staurosporine treated. (A–F) Data from
two donors, three independent experiments. (G and H) Data are representative of four independent experiments from two donors.
Fractalkine is an SMC survival factor and mitogen 831Figure 5 CX3CL1 induces shedding of epiregulin within 10 min, leading to de novo synthesis of epiregulin mRNA and protein after 2 h. (A–C)
Cells were serum-starved for 48 h prior to treatment with 30 nmol/L CX3CL1 for the indicated times. Real-time SYBR green RT–PCR was
performed for the indicated genes and the housekeeping gene GAPDH. Copy number for each gene was quantiﬁed from a genomic DNA
standard curve, and data normalized by dividing by copy number of GAPDH. Data are expressed as fold change over untreated. (D) Cells
were pre-treated for 1 h with AG1478 (1 mmol/L), PTX (250 ng/mL), GM6001 (10 mmol/L), or AZ12201182 (500 nmol/L) prior to the addition
of CX3CL1 for 2 h and mRNA quantitation of epiregulin as in (C). (E) CASMC were stained with anti-epiregulin antibody (dashed black line) or
isotype control (solid grey line) and analysed by ﬂow cytometry. (F) CASMC were treated with vehicle (dashed black line) or 200 nmol/L PMA
(solid black line) for 30 min prior to staining with anti-epiregulin antibody by ﬂow cytometry. (G) CASMC were treated with vehicle (dashed
black line) or 30 nmol/L CX3CL1 for 10 min (solid black line) or 2 h (solid grey line) and analysed for epiregulin expression as in (F). (H)
CASMC were pre-treated for 1 h with anti-epiregulin antibody or isotype control (20 mg/mL) prior to the addition of CX3CL1 (30 nmol/L)
and quantitation of DNA synthesis. (I) CASMC were pre-treated with antibody as in (H) prior to the addition of PDGF-BB (1 nmol/L) or
CXCL8 (30 nmol/L) and quantitation of DNA synthesis. All data shown as mean+SEM. Data analysed by one-way ANOVA and Dunnett’s
or Tukey’s post hoc test. ***P , 0.001, **P , 0.01 relative to untreated, þþþP , 0.001, þþP , 0.01, ns is not signiﬁcant relative to
CX3CL1 treated. (A–C) Data from three donors, four independent experiments. (D) Data from two independent experiments. (E–G)
Data are representative of two independent experiments, three ﬂasks per treatment in each experiment. (H) Data from three independent
experiments. (I) Data from two independent experiments.
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the 10 min time-point (Figure 4H), indicating that Akt is activated
via the EGFR.
3.6 CX3CL1 induces synthesis of the
extracellular EGFR ligand epiregulin
Since the broad-spectrum metalloprotease inhibitor GM6001 was
able to block CX3CL1-induced DNA synthesis and anti-apoptosis,
wehypothesizedthatCX3CL1signallinginvolvedreleaseofanextra-
cellularEGFR ligandwithin theﬁrst 6 hofCX3CL1 treatment. Using
real-time SYBR greenPCR, weanalysedthe expression ofthe EGFR
ligandsepiregulin,heparin-bindingEGF-likegrowthfactor(HB-EGF),
amphiregulin, TGFa, and EGF over a time-course of CX3CL1 treat-
ment. CX3CL1 induced a 20-fold up-regulation in epiregulin mRNA
within 2 h (P , 0.01, Figure 5A), but had no effect on mRNA
expression of HB-EGF or other EGFR ligands (Figure 5B and data
not shown). In addition, levels of the EGFR itself were unaffected
by CX3CL1 treatment over the time-course analysed (Figure 5C).
We next investigated the pathways required for the observed
upregulation in epiregulin mRNA. Pre-treatment with the
CX3CR1 inhibitor AZ12201182 or pertussis toxin abrogated the
induction of epiregulin by CX3CL1 at the 2 h time-point, conﬁrm-
ing the speciﬁcity of the response (P , 0.01, Figure 5D). In addition,
treatment with both AG1478 and GM6001 completely blocked
the increase in epiregulin mRNA, indicating that EGFR activation
via the extracellular pathway is required for this effect (P , 0.01,
Figure 5D).
To conﬁrm whether epiregulin protein expression was affected
by CX3CL1 treatment, we performed ﬂow cytometry to detect
cell-associated epiregulin at early (10 min) and later (2 h) time-
points after CX3CL1 treatment. Untreated cells showed substan-
tial epiregulin expression compared with the isotype control,
though not all cells within the population expressed epiregulin
(Figure 5E, dashed line). To conﬁrm whether epiregulin shedding
could be detected by ﬂow cytometry, we treated cells with
200 nmol/L PMA, which is a broad-spectrum activator of metallo-
proteases and previously shown to induce epiregulin shedding.
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Treatment with PMA resulted in loss of epiregulin expression
within 30 min (Figure 5F, solid line), indicating cleavage and
release of epiregulin from the cell. Similarly, CX3CL1 treatment
for 10 min resulted in loss of epiregulin expression detectable by
ﬂow cytometry (Figure 5G, solid black line), indicating a rapid shed-
ding from the cell in response to CX3CL1. After 2 h CX3CL1
treatment, there was a re-appearance of epiregulin expression
(Figure 5G, solid grey line), indicating de novo synthesis of epiregulin
protein, conﬁrming our ﬁndings at the mRNA level. These data
show that CX3CL1 induces both the rapid shedding of epiregulin
and regulates epiregulin expression over a longer time-course.
To conﬁrm whether epiregulin shedding is essential for the
mitogenic effect of CX3CL1, we used a neutralizing antibody
against CX3CL1 in the tritiated thymidine incorporation assay.
Anti-epiregulin antibody but not isotype control abrogated the
induction of DNA synthesis by CX3CL1 (P , 0.001, Figure 5H).
DNA synthesis in response to PDGF-BB and CXCL8 were unaf-
fected by the addition of anti-epiregulin antibody, conﬁrming the
speciﬁcity of the blockade (Figure 5I). Thus, CX3CL1 induces
shedding of epiregulin leading to EGFR activation and proliferation
of CASMC.
4. Discussion
We have demonstrated for the ﬁrst time that CX3CL1 has prolif-
erative and anti-apoptotic effects on primary human SMCs which
are mediated via the EGFR. Furthermore, we identify critical
roles for ERK and PI3K signalling and identify the EGFR ligand epir-
egulin as an autocrine/paracrine growth factor regulated by
CX3CL1.
4.1 Apoptosis
The novel ﬁnding that CX3CL1 is a survival factor for VSMCs has
important implications for the development of vascular disease and
supports recent data showing a role for CX3CL1 in murine mono-
cyte survival. Landsman et al.
20 demonstrated that deletion of
either CX3CL1 or CX3CR1 results in a signiﬁcant reduction of cir-
culating monocytes in mice: particularly those of the Gr1
low ‘resi-
dent’ subset. When fed a high fat diet, these mice develop smaller
lesions which contain more apoptotic cells than those in wild-type
mice: implying a direct and pro-atherogenic effect of CX3CL1 on
monocyte survival.
In this study, CX3CL1-induced Akt phosphorylation and the
activity of PI3K were shown to be essential for blockade of apop-
tosis. In contrast, ERK signalling was not associated with the anti-
apoptotic effects of CX3CL1. Our data are in agreement with
those of Vantler et al.
21 who systematically demonstrated that
only PI3K signalling is required for the anti-apoptotic effects of
growth factors on SMCs. The downstream mechanism by which
CX3CL1 blocks apoptosis is still unknown, but could involve
rapid induction of anti-apoptotic proteins. Indeed, blockade of
staurosporine-induced apoptosis by EGF in an esophogeal carci-
noma cell line was shown to require induction of the Bcl-2
family member Mcl-1.
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4.2 Proliferation
Using assays to measure de novo DNA synthesis, Ki67 expression,
and cell counting, CX3CL1 (30 nmol/L) was shown to have mito-
genic activity equivalent to that obtained with 1 nmol/L
PDGF-BB: a potent SMC mitogen. To our knowledge, only a few
chemokines have been shown to have a role in human SMC pro-
liferation, including CCL2 (MCP-1) and CXCL8 (IL-8;
Figure 2F).
23,24 Thus, CX3CL1 joins a select few chemokines
which have this property, suggesting it has a key role in pathologies
involving SMC proliferation. In preliminary experiments, we have
also shown that CX3CL1 induces DNA synthesis in saphenous
vein SMCs, implicating CX3CL1 as a mitogen for SMCs of both
venous and arterial origin (data not shown). The dose of
CX3CL1 used in this study is in line with other published studies
investigating functional effects of chemokines on SMCs and corre-
sponds to the dose used to obtain peak SMC chemotaxis in a pre-
vious publication from our laboratory.
8,18,24
In contrast to anti-apoptotic effects, the mitogenic function of
CX3CL1 depends on both ERK and PI3K activation since both
the MEK inhibitor U0126 and the PI3K inhibitor LY294,002 are
able to block DNA synthesis. However, our signalling assays
Fractalkine is an SMC survival factor and mitogen 833clearly demonstrate that ERK and PI3K exist in separate pathways:
ERK is directly downstream of CX3CR1, while PI3K activation is
dependent on epiregulin acting via the EGFR (Figure 6). Our data
are consistent only with a model whereby dual activation of
both ERK and PI3K is essential for proliferation to proceed,
whereas anti-apoptosis does not require ERK activation.
4.3 EGFR involvement
Previous studies have demonstrated the activation of both ERK and
Akt in response to CX3CL1 in other cell types.
25 However, this is
the ﬁrst time that EGFR activity has been shown to be involved in
CX3CR1 signalling and essential for both mitogenic and anti-
apoptotic activity. The EGFR has been implicated in the prolifer-
ation of several transformed cell lines in response to chemokines,
and is involved in the regulation of matrix metalloprotease
expression in primary SMCs by CCL11 (eotaxin) and CXCL12
(SDF-1a).
18 We have shown that CX3CL1 induces rapid shedding
of the EGFR ligand epiregulin and subsequently induces further
epiregulin synthesis via EGFR activation. Epiregulin is a potent
mitogen for rat aortic SMCs and is induced by the GPCR agonists
endothelin-1, angiotensin II, and thrombin.
26 Furthermore, epiregu-
lin is an autocrine/paracrine de-differentiation factor for SMCs and
is expressed in human atherosclerotic plaques and balloon-injured
rat arteries, but not in normal vessels.
27 Intriguingly, PMA-induced
epiregulin shedding in mouse embryonic ﬁbroblasts is dependent
on ADAM17 (TACE),
19 the metalloproteinase required for
CX3CL1 cleavage from SMCs.
6 Our work identiﬁes a mechanism
by which CX3CL1 signalling may be ampliﬁed to induce SMC pro-
liferation and survival and contribute to vascular pathology.
4.4 CX3CL1 as a therapeutic target
We show for the ﬁrst time that CX3CR1 activation can be blocked
by the novel and speciﬁc antagonist AZ12201182. This compound
was found to inhibit the pro-survival and mitogenic effects of
CX3CL1, and block the induction of epiregulin mRNA in response
to CX3CL1. This compound may prove to be a useful tool for
further analysis of CX3CR1 function, and suggests the possibility
of therapeutic CX3CR1 blockade by small molecule inhibitors.
In conclusion, we provide evidence of a novel function for
CX3CL1 in human SMC anti-apoptosis and proliferation, via a
mechanism involving ERK, PI3K, Akt, and the EGFR. This has
important implications in vascular pathologies, including athero-
sclerosis, restenosis, and transplant accelerated arteriosclerosis,
where the balance of SMC proliferation and apoptosis critically
determines both plaque stability and vessel stenosis.
Supplementary material
Supplementary material is available at Cardiovascular Research
online.
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